Related Experiment Videos
Indications for directional coronary atherectomy: 1993
1Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195.
The American Journal of Cardiology
|October 18, 1993
Summary
Directional coronary atherectomy removes plaque, offering benefits over balloon angioplasty for specific coronary stenoses. However, it does not solve restenosis caused by intimal hyperplasia.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Medical Device Technology
Background:
- Balloon angioplasty has limitations in treating coronary stenoses.
- New devices aim to overcome these limitations.
- Directional coronary atherectomy (DCA) was the first FDA-approved device of its kind.
Purpose of the Study:
- To evaluate the efficacy and utility of directional coronary atherectomy compared to balloon angioplasty.
- To identify specific lesion characteristics where DCA may offer an advantage.
Main Methods:
- Review of nonrandomized clinical experience with DCA.
- Comparison of outcomes with balloon angioplasty.
- Consideration of data from randomized trials like CAVEAT.
Main Results:
- DCA removes atherosclerotic plaque, creating a smoother surface with less recoil.
- It shows promise in specific lesions: ostial, bifurcation, proximal LAD, vein grafts, complex, eccentric, and those failing PTCA.
- DCA yields minimal residual stenosis and larger lumen diameters in suitable lesions.
- Adverse events like dissection and acute closure appear infrequent and potentially improved over balloon angioplasty.
Conclusions:
- DCA offers a distinct mechanism for treating coronary stenoses, with demonstrated benefits in specific lesion types.
- It does not resolve the issue of intimal hyperplasia and subsequent restenosis.
- Further targeted randomized trials are needed to fully define DCA's role and optimal lesion selection.